Aptorum Group Limited (APM) Stock Score, Valuation & Financial Research

Aptorum Group Limited is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for APM

Aptorum Group Limited does not currently have a complete Wall Street Score. The stored market price is USD 8.26. These figures are a research snapshot, not a buy or sell recommendation.

What Aptorum Group Limited does

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Aptorum Group is a clinical-stage biopharmaceutical company that generates revenue primarily through the commercialization of nutraceutical products and potential future licensing or milestone payments from its pipeline of therapeutic drug candidates. The company focuses on research and development in areas such as neurology, infectious diseases, and oncology, relying on capital raises and strategic collaborations to fund its ongoing operations and clinical trials.

Products and services

  • The company develops novel therapeutics for orphan diseases, infectious diseases, and metabolic disorders, and commercializes Dioscorea opposita-based nutraceutical tablets for women's health.

Brands and product families

  • Dioscorea opposita Bioactive Nutraceutical Tablets — Nutraceutical product for women's health. Source

Customer types

Healthcare providers and patients.

Business relationships and partnerships

  • DiamiR Biosciences Corp. — Aptorum entered into a merger agreement with DiamiR Biosciences Corp. on July 14, 2025, involving intellectual property licensing and management services agreements. Source

Business strengths to evaluate

  • Diverse pipeline of therapeutic projects in multiple disease areas Source

Business risks and research considerations

  • Uncertainty regarding regulatory approval for drug candidates Source
  • Dependence on capital raises and external funding to sustain operations Source

Sources: Company research source · Dioscorea opposita Bioactive Nutraceutical Tablets · DiamiR Biosciences Corp. · Diverse pipeline of therapeutic projects in multiple disease areas · Uncertainty regarding regulatory approval for drug candidates · Dependence on capital raises and external funding to sustain operations

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

APM financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 8.26
Market capitalization:
5.24M (currency not supplied)
Revenue:
USD 960.82K
Net income:
USD -6.39M
Free cash flow:
USD -1.84M
Cash:
USD 1.83M
Total debt:
USD 3.51M
EPS:
USD -5.12

What stands out

  • Free cash flow is USD -1.84M, negative for the stored period.
  • The balance sheet shows USD 1.83M of cash versus USD 3.51M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -191.1% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -664.8% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 1.67M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for APM

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can APM fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does APM's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for APM to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of APM's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-02.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research APM

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.